Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Milestone Pharmaceuticals ( (MIST) ) has issued an announcement.
On July 10, 2025, Milestone Pharmaceuticals amended its Royalty Purchase Agreement with RTW Investments, extending the marketing approval deadline for etripamil to December 31, 2025. The following day, the company announced that the FDA accepted its response to a Complete Response Letter for CARDAMYST, assigning a new PDUFA target action date of December 13, 2025. This extension and FDA acceptance are pivotal for Milestone, as they secure potential funding and advance the approval process for CARDAMYST, positioning the company for a successful launch in the PSVT market.
The most recent analyst rating on (MIST) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Milestone Pharmaceuticals stock, see the MIST Stock Forecast page.
Spark’s Take on MIST Stock
According to Spark, TipRanks’ AI Analyst, MIST is a Underperform.
Milestone Pharmaceuticals’ overall stock score reflects substantial financial difficulties, including no revenue and negative cash flows. However, the upcoming launch of CARDAMYST provides a potential turnaround opportunity, which is a significant positive factor. Technical indicators suggest a bearish trend, and valuation metrics highlight the lack of earnings and dividends, indicating a speculative investment.
To see Spark’s full report on MIST stock, click here.
More about Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular solutions to improve the lives of people with complex heart conditions. The company’s lead investigational product is etripamil, a novel calcium channel blocker nasal spray designed for self-administration by patients to treat symptomatic episodic attacks associated with paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR).
Average Trading Volume: 1,051,863
Technical Sentiment Signal: Buy
Current Market Cap: $128.3M
Learn more about MIST stock on TipRanks’ Stock Analysis page.